Case Report: Remarkable response to savolitinib plus chemotherapy and bevacizumab in second-line treatment of MET amplified colon cancer with liver metastasis.

Ying Huang, Pei Shu, Shiyuan Gu, Feng Wen, Xin Wang

Abstract readCase Reports

In one paragraph

Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ying Huang *Division of Abdominal Tumor Multimodality Treatment, Cancer Center, West China Hospital of Sichuan University, Chengdu, China.

Pei Shu *Division of Abdominal Tumor Multimodality Treatment, Cancer Center, West China Hospital of Sichuan University, Chengdu, China.

Shiyuan Gu *Division of Abdominal Tumor Multimodality Treatment, Cancer Center, West China Hospital of Sichuan University, Chengdu, China.

Feng WenDivision of Abdominal Tumor Multimodality Treatment, Cancer Center, West China Hospital of Sichuan University, Chengdu, China.

Xin WangDivision of Abdominal Tumor Multimodality Treatment, Cancer Center, West China Hospital of Sichuan University, Chengdu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Metastatic colorectal cancer (mCRC) is associated with poor prognosis and low survival rates, with acquired resistance limiting the durability of standard therapies. Mesenchymal-epithelial transition factor (MET) amplification is a rare but potentially actionable molecular alteration that has been implicated in treatment resistance, while clinical evidence supporting MET-directed combination therapy in mCRC remains limited. Case presentation: We report a rare case of a young patient with KRAS/NRAS/BRAF wild-type descending colon cancer with liver metastases and Conclusion: Our findings suggest that the addition of savolitinib to standard chemotherapy and a VEGF inhibitor may have contributed additional antitumor activity in this patient with MET-amplified mCRC. However, the independent contribution of savolitinib cannot be determined, and this observation should be regarded as hypothesis-generating and warrants validation in prospective studies.

Indexed as

bevacizumabchemotherapycombination therapyMET amplificationmetastatic colorectal cancersavolitinib

Identifiers

PMID42745771

DOI10.3389/fonc.2026.1861675

PMCPMC13574568

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.